Bli medlem
Bli medlem

Du är här


NANOBIOTIX: NANOBIOTIX presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer at the Society for Immunotherapy of Canc

Paris, France and Cambridge, Massachusetts, USA, November 14, 2016
-NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205)
, a late clinical-stage nanomedicine company pioneering novel approaches for
the local treatment of cancer, today announces preclinical data demonstrating
that its leading radioenhancer nanoparticle, NBTXR3, actively stimulates the
host immune system to attack tumor cells. These data from the ongoing NBTXR3
immuno-oncology preclinical program were presented at one of the leading
global immuno-oncology conferences, the31st Annual Meeting of the Society for
Immunotherapy of Cancer (SITC), being held November 9-13, 2016 in National
Harbor, Maryland, USA (Paris S., Pottier A., Levy L., and Lu B. Hafnium oxide
nanoparticles, a radiation enhancer for in situ cancer vaccine).

Laurent Levy, CEO of Nanobiotix, commented: "These exciting data show that
NBTXR3 could be a potential game changer in
Immuno-oncology combination landscape. This raises the possibility of
synergies between NBTXR3, radiotherapy and immunotherapies. On the top of
existing core developments of our product as a single agent, this is opening
new doors for industrial collaborations.

Data presented showing the potential of NBTXR3 in Immuno-Oncology

During the presentation, Nanobiotix scientists and Dr. Bo Lu, MD, Director of
the Molecular Radiation Biology in the Department of Radiation Oncology at
the Thomas Jefferson University Hospital in Philadelphia, presented study
results which demonstrate that radiotherapy with NBTXR3 elicits a marked
enhancement of Immunogenic Cell Death (ICD) compared to radiotherapy alone
across different cancer cell lines, in radioresistant or radiosensitive

In a second experiment, the phenomenon known as the abscopal effect was
evaluated (i.e. an effect outside the scope of the localized treatment). Two
tumors were implanted on both sides of mice, and subsequently only one tumor
was treated with NBTXR3-radiation therapy. As a result, both tumors
demonstrated volume shrinkage. Specifically, the study showed that use of
NBTXR3 in combination with radiotherapy resulted in a control on the
untreated tumor and a statistically significant increase of overall survival.
No abscopal effect was observed in control groups and group treated with
radiation therapy alone.

A third experiment has demonstrated that NBTXR3 combined with radiotherapy
could be used to create a vaccineex vivo
with a higher rate of long term vaccination success when compared to
radiotherapy alone.

Elsa Borghi, CMO of Nanobiotix commented: "Although immunotherapies hold great
promise in treating cancer, one of the
main barriers is that most of tumors do not provoke an immune response, which
renders immunotherapy ineffective in many patients. The findings from this
research indicate that NBTXR3 could have the potential to transform a tumor
into an in situ vaccine. It could convert an immunologically 'cold' tumor,
which does not provoke an immune response, to a 'hot' tumor, which induces an
immune response and therefore provokes a host immune response to attack tumor

NBTXR3 competitive positioning in Immuno-Oncology

Radiotherapy is an established standard of care in many solid tumor types
(approximately 60% of all cancer patients receive radiotherapy). Compared to
other products used for priming of the tumor, currently in development for
Immuno-Oncology, NBTXR3 could have a number of advantages: a physical and
universal mode of action that could be used widely across oncology, one time
local injection, a good fit within existing medical practice already used a
base for cancer treatment, limited or no systemic toxicity, and a
well-established manufacturing process.

Radiotherapy is often given within the first lines of cancer treatment,
compare to most current positioning of immuno-oncology development in a later
stage treatment. A successful approach using NBTXR3 in immuno-oncology could
make it a key player by offering treatment options in earlier stages of the

Taken together, these data indicate that radiotherapy in combination with
NBTXR3 could play a key role in immuno- oncology and could be used in synergy
with several immuno-oncology approaches to increase patient responses across
many different types of cancer.

NBTXR3 current clinical development as a single agent

Outside immuno-oncology field and as a single agent, NBTXR3 is in late stage
clinical development, for its capability to enhance the dose of radiotherapy
within the tumor and more efficiently destroy cancer cells. Worldwide
clinical development is currently covering seven patient populations and a
first market approval has been filed in EU in August 2016.


About NBTXR3

Nanobiotix's lead product, NBTXR3, is a first-in-class radio-enhancer
nanoparticle designed for direct injection into cancerous tumors. It has been
engineered to increase the dose and efficacy of radiotherapy without
increasing toxicity or causing damage to surrounding healthy tissues. NBTXR3
is currently in late-stage clinical development as a single agent.

Worldwide clinical development of NBTXR3 now includes trials across 7 patient

* Soft Tissue Sarcoma (STS)

Phase I/II trial completed

Phase II/III "" global trial (including EU, South
Africa and Asia-Pacific region)

* Head and Neck Cancer

Phase I/II trial in France and Spain; NBTXR3 + Radiotherapy alone

Phase I/II trial by PharmaEngine in Asia-Pacific; NBTXR3 +

* Prostate Cancer

Phase I/II trial in the U.S

* Liver Cancers

Phase I/II Hepatocellular Cancer trial in France

Phase I/II Liver Metastases trial in France

* Rectal Cancer

Phase I/II trial by PharmaEngine in Asia-Pacific

First market approval has been filed in the EU and could be obtained in 2017.


Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage
nanomedicine company pioneering novel approaches for the local treatment of
cancer. The Company's first-in-class, proprietary technology, NanoXray,
enhances radiotherapy energy with a view to provide a new, more efficient
treatment for cancer patients.

NanoXray products are compatible with current radiotherapy treatments and are
meant to treat potentially a wide variety of solid tumors including soft
tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast
cancer, glioblastoma, etc., via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under
clinical development for soft tissue sarcoma, head and neck cancer, prostate
cancer, and liver cancers (HCC and liver metastases) as well as head and neck
and rectal cancers under trial by PharmaEngine. The Company has filed in
August 2016 for market approval (CE Marking) in Europe for its lead product
NBTXR3. The Company has partnered with PharmaEngine for clinical development
and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN:
FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company
Headquarter is based in Paris, France. Affiliate in Cambridge, United States.

For more information, please


| Nanobiotix |
| Sarah Gaubert |
| |
|Head of Communication and Public Affairs |
|+33 (0)1 40 26 07 55 |
| |
| Media relations |
| France -Springbok Consultants EU Outside France -Instinctif Partners United States -The Ruth Group |
| |
|Marina Rosoff Melanie Toyne Sewell Kirsten Thomas / Chris Hippolyte |
| |
|+33 (0)6 71 58 00 34 +44 (0) 207 457 2020 +1 508-280-6592 / +1 646-536-7023 |
| |

This press release contains certain forward-looking statements concerning
Nanobiotix and its business. Such forward-looking statements are based on
assumptions that Nanobiotix considers to be reasonable. However, there can be
no assurance that the estimates contained in such forward-looking statements
will be verified, which estimates are subject to numerous risks including the
risks set forth in the
reference document of Nanobiotix filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) under number D.16-0732 on July
22, 2016
(a copy of which is available on and to the development of
economic conditions, financial markets and the markets in which Nanobiotix
operates. The forward-looking statements contained in this press release are
also subject to risks not yet known to Nanobiotix or not currently considered
material by Nanobiotix. The occurrence of all or part of such risks could
cause actual results, financial conditions, performance or achievements of
Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an
offer to sell or subscribe for, or a solicitation of an offer to purchase or
subscribe for, Nanobiotix shares in any country.

NBTXR3 immuno-oncology vaccin in situ potentiel

This announcement is distribute...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.